Menu Back toSafe-Use-and-Prescribing-of-Opioid-Medications-An-In-Depth-Look-at-the-Strategies-and-Their-Evaluation

DIA 2018 Global Annual Meeting

Safe Use and Prescribing of Opioid Medications: An In-Depth Look at the Strategies and Their Evaluation

    Session Chair(s)
      Sidney H. Schnoll, MD, PhD

      Sidney H. Schnoll, MD, PhD

      • Vice President, Pharmaceutical Risk Management
      • Pinney Associates, Inc, United States
    Prescription opioids can be used to treat moderate-to-severe pain, such as pain following surgery or injury, in health conditions such as cancer, and in chronic, non-cancer conditions such as back pain or osteoarthritis. More than 25 million Americans suffer from daily chronic pain, and prescription opioid therapy has been instrumental in helping patients manage their symptoms and achieve a better quality of life. However, it is estimated that more than 2 million Americans have opioid use disorder (OUD), and that millions more misuse opioids, taking these medications longer or in higher doses than prescribed. The problem has reached a level of crisis, as an average of 115 Americans die each day from an overdose of opioids, either prescription or heroin. According to CDC statistics, the number of overdose deaths involving opioids increased five-fold from 1999 to 2016, driven largely by prescription opioids.

    These alarming increases in opioid-related harms have mobilized the US health system to implement strategies to support safe use and appropriate prescribing behaviors. This session will examine the framework and current strategies for a well-balanced approach aimed at reducing the supply of opioids vulnerable to misuse and mitigating risks through more judicious prescribing. Panelists will discuss the critical need and ways to assess the impact of these strategies on patient health outcomes and public health in order to avoid creating barriers to appropriate treatment for both acute and chronic pain.
    Learning Objective : Describe strategies to promote the safe use and prescribing of opioids within a framework balancing safe prescribing and appropriate pain management; risk mitigation; and patient access; Discuss how these strategies were implemented; barriers and potential unintended consequences of adoption ; Discuss needs for evidence to support existing strategies and how success may be defined and measured
      Judy Anne Staffa, PhD, RPh

      Safe Use of Opioids: FDA Perspective

      Judy Anne Staffa, PhD, RPh

      • Associate Director for Public Health Initiatives, OSE, CDER
      • FDA , United States
      Alton  Johnson, PhD, RPh

      Feedback on Proposed Burdensome Regulation for Opioids

      Alton Johnson, PhD, RPh

      • Vice President, Global Technology Services
      • Pfizer Inc, United States
      Veeraindar  Goli

      Clinician/Drug Development Perspective

      Veeraindar Goli

      • Senior Director, CNS Center of Excellence
      • IQVIA, United States